Thymopoietin Beta and Gamma Isoforms as a Potential Diagnostic Molecular Marker for Breast Cancer: Preliminary Data

详细信息    查看全文

• 作者：Daniel Marrero-Rodríguez ; Keiko Taniguchi-Ponciano…
• 关键词：Thymopoietin ; Isoforms ; Molecular marker ; Breast cancer
• 刊名：Pathology & Oncology Research
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：21
• 期：4
• 页码：1045-1050
• 全文大小：612 KB
• 参考文献：1.Knaul FM, Nigenda B, Lozano R, Arreola H, Langer A, Frenk J (2008) Breast cancer in Mexico: a pressing priority. Reprod Health Matters 16:113-23CrossRef PubMed
  2.Cantile M, Pettinato G, Procino A, Feliciello I, Cindolo L, Cillo C (2003) In vivo expression of the whole HOX gene network in human breast cancer. Eur J Cancer 39:257-64CrossRef PubMed
  3.Harris C, Andryuk P, Cline S, Mathew S, Siekerka J, Goldstein G (1995) Structure and mapping of the human thymopoietin (TMPO) gene and relationship of human TMPO B to rat lamin-associated polypeptide 2. Genomics 28:198CrossRef PubMed
  4.Ward M, van der Watt P, Tzoneva G, Leaner V (2011) Deregulated LAP2a expression in cervical cancer associates with aberrant E2F and p53 activities. IUBMB Life 11:1018-026CrossRef
  5.Parise P, Finocchiaro G, Masciadri B, Quarto M, Francois S, Mancuso F et al (2006) Lap2α expression is controlled by E2F and deregulated in various human tumors. Cell Cycle 12:1331-341CrossRef
  6.LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V et al (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62:4499-06PubMed
  7.Agrawal D, Chen T, Irby R, Quackenbush J, Chambers A, Szabo M et al (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513-21CrossRef PubMed
  8.Marrero D, Peralta R, Valdivia A, De la Mora A, Romero P, Parra M et al (2012) The neurofibromin 1 type I isoform predominance characterises female population affected by sporadic breast cancer: preliminary data. J Clin Pathol 5:419-23CrossRef
  9.Hugh J, Hanson J, Chon U, Nielsen T, Perou C, Dumontet C et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 8:1168-176CrossRef
  10.Dorner D, Vlcek S, Foeger N, Gajewski A, Makolm C, Gotzmann J et al (2006) Lamina-associated polypeptide 2α regulates cell cycle progression and differentiation via the retinoblastoma–E2F pathway. J Cell Biol 1:83-3CrossRef
  11.Kim H, Hwang H, Han M, Baek S, Sim H, Yoon S et al (2012) LAP2 Is widely overexpressed in diverse digestive tract cancers and regulates motility of cancer cells. Plos One 6:e39482CrossRef
  12.Taylor MR, Slavov D, Gajewski A, Vlcek S, Ku L, Fain PR et al (2005) Thymopoietin (Lamina-Associated Polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat 6:566-74CrossRef
  13.Dechat T, Gotzmann J, Stockinger A, Harris C, Talle M, Siekierka J et al (1998) Detergent-salt resistance of LAP2α in interphase nuclei and phosphorylation-dependent association with chromosomes early in nuclear assembly implies functions in nuclear structure dinamics. EMBO J 17:4887-902PubMed Central CrossRef PubMed
  14.McCafferty M, Healy N, Kerin M (2009) Breast cancer subtypes and molecular biomarkers. Diagn Histopathol 15:485-89CrossRef
  15.Staples E, Gasiewicz T, Fiore N, Lubahn D, Korach K, Silverstone A (1999) Estrogen receptor is necessary in thymic development and estradiol-induced thymic alterations. J Anat 163:4168-174
  16.Ertel A, Dean J, Rui H, Liu C, Witkiewicz A, Knudsen KE et al (2010) RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeuti responsse. Cell Cycle 20:4153-163CrossRef
  17.Zhang S, Liu S, Al-Saleem L, Holloran D, Babb J, Guo X et al (2000) E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 9:395-01
  18.Moroy T, Heyd F (2007) The impact of alternative splicing in vivo: mouse models show the way. RNA 13:1155-171PubMed Central CrossRef PubMed
  19.Venables J, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C et al (2008) Identification of alternative splicing markers for breast cancer. Cancer Res 22:9525-531CrossRef
  20.Vlcek S, Korbei B, Foisner R (2002) Distinct functions of the unique C terminus of LAP2 in cell proliferation and nuclear assembly. J Biol Chem 21:18898-8907CrossRef
  21.Martins S, Eikvar S, Furukawa K, Collas P (2003) HA95 and LAP2 mediate a novel chromatin–nuclear envelope interaction implicated in initiation of DNA replication. J Cell Biol 2:177-88CrossRef
  22.Gant T, Harris C, Wilson K (1999) Roles of LAP2 proteins in nuclear assembly and DNA replication: truncated LAP2b proteins alter lamina assembly, envelope formation, nuclear size, and DNA replication efficiency in Xenopus laevis extracts. J Cell Biol 6:1083-096CrossRef
  23.Dechat T, Vlcek S, Foisner R (2000) Review: lamina-associated polypeptide 2 isoforms and related proteins in cell cycle-dependent nuclear structure dynamics. J Struct Biol 129:335-45CrossRef PubMed
  
• 作者单位：Daniel Marrero-Rodríguez (1) (2)
  Keiko Taniguchi-Ponciano (1)
  Julio Lopez-Sleman (1)
  Pablo Romero-Morelos (1)
  Monica Mendoza-Rodríguez (1)
  Israel Garcia (3)
  Victor Huerta-Padilla (1)
  Alejandra Mantilla (4)
  Armando Duarte (5)
  Patricia Pi?a (1)
  Miriam Rodriguez-Esquivel (1)
  Ricardo Lopez-Romero (1)
  Jorge Parrazal-Romero (1)
  Salvador Tobias-Alonso (6)
  Florinda Jimenez-Vega (2)
  Mario Alvarez-Blanco (7)
  Mauricio Salcedo (1)
  
  1. Laboratorio de Oncología genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de Oncología, CMN-SXXI. IMSS, Av. Cuauhtémoc 330, Col. Doctores, México, DF, 06720, Mexico
  2. Laboratorio de Biotecnología, Universidad Autonóma de Ciudad Juárez, Chihuahua, Mexico
  3. Servicio de Ginecología Oncológica, Hospital de Oncología CMN-SXXI, IMSS, Mexico, Mexico
  4. Servicio de Patología, Hospital de Oncología CMN-SXXI, IMSS, Mexico, Mexico
  5. Clínica de Mama, Hospital General de Zona #35, IMSS, Cd. Juárez, Chihuahua, Mexico
  6. Departamento de Patología, Hopital General, Cd. Juarez, Chihuahua, Mexico
  7. Unidad de Quimioterapia, Servicio de Oncología, Hospital General de Mexico, S.S., Mexico, Mexico
  
• 刊物主题：Cancer Research; Oncology; Pathology; Immunology; Biomedicine general;
• 出版者：Springer Netherlands
• ISSN：1532-2807

文摘

Thymopoietin (TMPO) is an inner nuclear membrane protein, the coding gene named equally, can give arise to six isoforms by alternative splicing. This gene has been found up regulated in several types of cancer. At present work, we evaluated the TMPO isoforms generated by alternative splicing as well as the protein signal detection in breast cancer samples. TMPO expression was analyzed by immunohistochemistry in tissue microarray containing 46 breast tissue samples including normal (n--), benign lesions (n--8) (fibroadenomas (n--), fibrocystic changes (n--), ductal hyperplasias (n--)) and breast carcinoma (n--2). Isoforms -α, ?οand -γ of TMPO were evaluated using RT-PCR; clinical-pathological correlation analysis were done by mean of X2. Neither the normal nor the benign lesions of the breast showed positive TMPO immunodetection, whilst 45 % of the breast carcinomas were immunopositive (p--.000), nine of ten positives carcinomas correspond to the Luminal A subtype. Further, alpha isoform was present in all breast samples analyzed; however, beta and gamma isoforms were only present in ten (p--.003) and 17 (p--.000), respectively, in the breast cancer samples. According with the present data, we suggest that TMPOβ and -γ isoforms could provide a potential reliable diagnostic marker for breast cancer. Keywords Thymopoietin Isoforms Molecular marker Breast cancer